Considering Changes in the Recommended Human Chorionic Gonadotropin Monitoring After Molar Evacuation

Obstet Gynecol. 2020 Jan;135(1):9-11. doi: 10.1097/AOG.0000000000003625.

Authors

Neil S Horowitz¹, Ross S Berkowitz, Kevin M Elias

Affiliation

¹ From the New England Trophoblastic Disease Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; email: Ross_Berkowitz@dfci.harvard.edu.

PMID: 31809444
DOI: 10.1097/AOG.0000000000003625

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Chorionic Gonadotropin
Female
Gestational Trophoblastic Disease*
Humans
Hydatidiform Mole*
Pregnancy

Substances

Chorionic Gonadotropin